Business Context and Reporting Period
This Form 8-K is a current report filed by Gemini Therapeutics, Inc. (not Disc Medicine, Inc.) on August 17, 2021, regarding events occurring on August 16, 2021. The company is incorporated in Delaware and trades on The Nasdaq Global Market under the symbol GMTX.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes.
Material Changes
The material change reported is the departure of a director:
- Director Departure: Jean George informed the company of her intent not to stand for re-election at the 2021 Annual Shareholder Meeting.
- Effective Date: Her term as a director and her roles on the Nominating and Corporate Governance Committee and the Compensation Committee will expire upon the conclusion of the Annual Meeting.
- Reason for Departure: The filing explicitly states the decision was not the result of any disagreement with the company regarding operations, policies, financial disclosures, accounting, or legal matters.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of business risks. Management commentary is limited to thanking Ms. George for her service and confirming the amicable nature of her departure.
Investor Verification Checklist
- Verify the correct registrant name is Gemini Therapeutics, Inc., as the input metadata referenced Disc Medicine, Inc.
- Confirm the date of the 2021 Annual Shareholder Meeting to determine the exact date Ms. George's term expires.
- Review the company's proxy statement for the 2021 Annual Meeting to see if a replacement director was nominated.
- Check subsequent filings to confirm the final composition of the Board of Directors and its committees.